This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Patent and Trademark Office (USPTO) today published a final rule announcing across-the-board fee increases of 7.5% The changes will take effect as of January 19, 2025. but scrapping the most controversial proposals from its April 2024 Notice of Proposed Rulemaking (NPRM).
On 25th March 2025, the Patent Office officially released the Draft Guidelines for Examination of Computer-Related Inventions (CRI), 2025 , for public consultations. On a quick glance at the guidelines, the guidelines include discussion surrounding all aspects of patenting software (novelty, inventive step, clarity, etc).
Robert Bosch Limited, filed an appeal before the Madras High Court, challenging the rejection of their Indian Patent Application No. The FER also cited Section 3(d), excluding claims 1 to 6 from patentability. Counsel for the appellant argued that the Controller erred in applying Section 3(m) to the claimed invention.
by Dennis Crouch The Supreme Court's 2024-2025patent docket has a growing number of cases awaiting consideration. I count fifteen pending cases that could reshape multiple facets of patent law. Celanese raises questions the the scope of the on-sale bar under the America Invents Act, particularly for secret processes.
Theinter partesreview provisions of the Leahy-Smith America Invents Act have been criticized for the propensity of the Patent Trial and Appeal Board (PTAB) to find invalid all or at least some of the challenged claims, frequently on obviousness grounds.Failure to so find, in addition to being less common has also often upheld on appeal, in view of (..)
Rajya Sabha MP Haris Beeran wrote to the Minister of Health and Family Welfare on December 20, 2024, urging the Central Government to invoke Section 100 (1) of the Patents Act with respect to local production of the rare disease Spinal Muscular Atrophy (SMA) treating drug Risdiplam. The next date of hearing is today, i.e. January 20, 2025.
The Guidelines were released by the Pontifical Commission have been in force within Vatican City State since 1 January 2025. Our Kat reflects on whether this decision raises questions about the current sufficiency/enablement standard for therapeutic use inventions and the prior art that may be cited against them.
Super kids Seven-year-old named Callie from Manchester won the Kids Invent Stuff and Taskmaster Education Competition supported by the UK's Intellectual Property Office. The winning invention was a bath tub that shoots tasks out one end and poops rubber ducks out of the other, which as the winning idea got made IRL. See you there!
In 2025, the National Aeronautics and Space Administration (NASA) is scheduled to once again bring man and machine to the lunar surface, this time under the name of the Greek goddess Artemis. However, the means to the ends have changed.
A quick glance at last week analysis of wrongful obtainment in the Indian patent landscape, discussing Delhi High Courts jurisdiction in ANI vs OpenAI, and the implications of a MoU between screen writers and music composers. The last day to send your applications is April 1, 2025. Bharathwaj Ramakrishnan discusses this issue.
The case highlights some interesting aspects of pharma IP strategy, particularly as related to manufacturing IP and whether this is best protected with patents or trade secrets. However, manufacturing patents bring with them a number of risks and potential pitfalls.
Assistant Controller: The Court Reminds the Patent Office to Give Reasons DHC recently remanded a patent rejection order to the IPO, which had rejected the application due to the applicant’s failure to submit a written statement on time. What does this reveal about the quality of patent grant/rejection orders?
If you are concerned your companys innovations are not being identified and evaluated for possible patent protection, resolve to implement or improve an invention capture process early in 2025. By efficiently identifying valuable inventions and taking steps to pursue patents, your company can gain a competitive edge.
The United States Patent and Trademark Office (USPTO) announced the finalized patent fee increases which will be taking effect on January 19, 2025. percent in fee collections from the current fees and are setting or adjusting 433 patent fees including 52 new patent fees that were not previously assessed.
The Paris Local Division of the Unified Patent Court (UPC) first substantive decision on patent validity in DexCom v Abbott ( UPC_CFI_230/2023 ), provides some interesting commentary on how much the description should be taken into account when interpreting the claims. DexCom alleged infringement by Abbott's FreeStyle Libre 2 products.
A quick glance at last week analysis of a Delhi HC judgment on the patentability of genetically modified salmonella bacteria, a look at the Philips DVD Case where the Court imposed heavy damages and costs, and a post-grant opposition leading to a revocation of Optimus Linelizoid patent. Anything we are missing out on? Chalo Delhi!
Comments Invited on AI Governance and Guidelines Development Report (February 27) The office of CGPDTM has invited comments on the Draft Guidelines for Processing Patent Applications of Ayush Systems and Related Inventions for providing clarity on the filing and processing of patent applications of Ayush Systems and related inventions.
GuestKats and InternKats will start in February 2025. The deadline for submissions to the IPKat Book of the Year awards is 31 January 2025. Vote here for your favourite books in the categories of patents, copyright (incl., Vote here for your favourite books in the categories of patents, copyright (incl.,
Comments Invited on AI Governance and Guidelines Development Report (February 27) The office of CGPDTM has invited comments on the Draft Guidelines for Processing Patent Applications of Ayush Systems and Related Inventions for providing clarity on the filing and processing of patent applications of Ayush Systems and related inventions.
by Dennis Crouch I recently provided a set of interesting data on the large number of patents that are “at risk” of being invalidated based on the Federal Circuit’s Cellect decision. The article takes a critical look at the practice of obviousness-type double patenting in the U.S. patent system. 4th 1216 (Fed.
A Single Bench of the MadHC, headed by Justice Senthilkumar Ramamoorthy, delivered an intriguing judgment on February 27, 2025, in Navya Network Inc. The Controller of Patents & Designs ( pdf ). The case involved an appeal against the order dated March 13, 2023, which had dismissed Patent Application No.
On April 3, 2024, the United States Patent and Trademark Office (USPTO) published a 266-page Notice of Proposed Rulemaking (NPRM) on “Setting and Adjusting Patent Fees during Fiscal Year 2025” (89 FR 23226), with proposed selective and in some cases extraordinary increases in fees for the fiscal years 2025-2029.
Merck Patent GmbH , No. 10, 2025), the Federal Circuit vacated and remanded a PTAB post-grant review (PGR) decision that had upheld the validity of Merck's patent against sales of a commercially available product. Continue reading this post on Patently-O. by Dennis Crouch In CQV Co., 2023-1027 (Fed.
Case background The case in Abbott v Sibio Technology related to Abbott's European patent EP 3831283 for an on-body glucose monitoring device. Abbott alleged that Sibionics' GS1 CGM product, offered for sale on the Sibionics' online shop, infringed their patent. Abbott appealed this decision to the UPC Court of Appeal.
Their asserted patent is directed to a cell culture media containing rHSA produced via plants genetically modified to include the human genes. A key feature of the patentedinvention is monomer purity. Continue reading this post on Patently-O. 10,618,951. Wuhan Healthgen Biotechnology Corp. 2023-1389 (Fed.
Here is our recap of last week’s top IP developments including summaries of the posts on IPO’s patent application rejection of HIV drug Dolutegravir, another judgement in the long-running Section 3(k) saga, this time on the patentability of business methods and the DHC IPD’s Annual Report 2023-24. Anything we are missing out on?
We are pleased to bring to you this sponsored post by IP Press on the extension of the registration deadlines for their Comprehensive Course on Patents, in collaboration with S. The IP Press presents the third cohort of the Comprehensive Course on Patents. Majumdar & Co.who are experts in the field of Patents.
by Dennis Crouch The Federal Circuit's recent decision in In re McLeay offers a glimpse into the evolving relationship between utility and enablement in patent law. In affirming the USPTO's rejection of claims for treating COVID-19 with aerosolized ribavirin, the court's February 18, 2025 ruling (No. Already a member?
5 Proven Steps to Protect Your Intellectual Property in 2025 In a world where ideas are currency, protecting intellectual property (IP) has ne ver been more critical. IP typically falls into the following categories: Patents : Cover inventions, processes, and designs that are new, useful, and non-obvious.
On March 26, 2025, Acting Director of the United States Patent and Trademark Office (USPTO) Coke Morgan Stewart issued a memorandum (the Workload Memorandum) to all Administrative Patent Judges (APJs) of the Patent Trial and Appeal Board (PTAB or the Board). By: Latham & Watkins LLP
Over to Ian : "In European Patent Office (EPO) opposition proceedings, a company accused of patent infringement has the right to intervene. In T 1286/23 , related to European patent 2941163, the Board of Appeal has questioned this approach and referred the matter to the Enlarged Board of Appeal for consideration.
Interview with Justice Prabha Sridevan on Expert Evidence and Judicial Practices in IP Litigation Date of Interview: January 21, 2025 Mode of Interaction: Questionnaire (Prepared and Shared in Advance), Conducted Over the Phone, Later Transcribed and Approved Profile of Justice (Retd.) Prabha Sridevan Justice (Retd.)
(Retd) Sukesh Behl ) in three cases concerning allegations of infringement of a Standard Essential Patent relating to Philips DVD player technology. Filed in 2012, the decision comes after 13 years with the litigation having outlived not only the suit patent, and the DVD industry, but also the institution that declared it essential !!
The referral will address a question relevant to every European patent application, namely how should the claims be interpreted? After all the UPC depends on patents approved for grant by the EPO. and Question 3) can a specification be a dictionary of definitions for the patent?
Here is our recap of last weeks top IP developments including summaries of the posts on unreasoned patent grants and rejections, the One Nation One Subscription initiative by the government, and the DHC order on missing reasons for ex-parte injunctions. The last date for submission of entries is March 31, 2025.
Notably, compared to those of ‘The Outline’ (2008) (see page 3 of the WIPO lexdoc ), the five-year goals set by ‘The Outline’ (2021–2035) are much more concrete and specific, as shown in the list below: The criterion of ‘The number of high-value inventionpatents* per 10,000 population’ had its debut this year at the 14th Five-Year Plan (2021–2025.
A later-filed, later-issued, earlier-expiring child patent cannot be used as an obviousness-type double patenting (ODP) reference against its first-filed, first-issued, later-expiring parent patent having a common priority date. 8,344,011 (the ’011 patent) and U.S. MSN Lab’ys Priv. 2024-1061, 2024 WL 3763599 (Fed.
Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?
The Copyright, Designs, and Patents Act 1988 of the United Kingdom, for instance, acknowledges computer-generated works; it defines the “author” as a person who makes the necessary arrangements for creating the work. UK Copyright, Designs, and Patents Act, 1988. However, the U.S. Baker McKenzie. Federal Register.
It summarizes the main IP rights (patents, trade marks, industrial designs, plant varieties and geographical indications) per the total number of worldwide filings, the number of IP rights in force and the year-on-year change. In the EU, the number of patent professionals in 2021 is 12,703.*
Patents , as a vital form of intellectual property (IP), safeguard these innovations, providing inventors and businesses exclusive rights to their inventions while promoting the dissemination of knowledge. As we move through 2024, several key patent trends are reshaping the future of innovation.
The IPKat has received and is pleased to host the following guest contribution by Katfriend Mindia Davitadze (Stockholm University) on the recent accession of Georgia to the European Patent Office (EPO) Validation System. As of now, there are two traditional routes to obtain patent protection for an invention in Georgia.
The particular litigation here centers on Natera’s US Patent No. Natera’s ‘035 patent is directed to methods for amplifying and sequencing cell-free DNA (cfDNA) to detect cancer. The technology in these cases has amazing potential and I have several friends who have used these techniques to detect early stage cancer.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content